Skip to main content

Sponsored By

Lilly
Interview with the Innovators
ESMO Early Breast Cancer

Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer

Videos - Interview with the Innovators

This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.

Nadia Harbeck, MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, German

Interview with the Innovators Presents:
Emerging Data in Early Breast Cancer from ESMO 2023

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.

Related Items
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
Jamie Carroll, APRN, CNP, MSN
Videos published on November 12, 2025 in Interview with the Innovators
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
Jamie Carroll, APRN, CNP, MSN
Videos published on November 10, 2025 in Interview with the Innovators
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
Heather Moore, PharmD, BCOP, CPP
Videos published on November 5, 2025 in Interview with the Innovators
Insights From the TRADE Study: Optimizing Abemaciclib Dose Escalation for Better Tolerability and Adherence
Heather Moore, PharmD, BCOP, CPP
Videos published on November 3, 2025 in Interview with the Innovators
TRADE Study Insights: A New Approach to Improve Abemaciclib Tolerability in Breast Cancer Care
Erica Mayer, MD, MPH
Videos published on October 28, 2025 in Interview with the Innovators
Optimizing Adjuvant Abemaciclib: Insights From the TRADE Study on Dose Escalation and Tolerability
Erica Mayer, MD, MPH
Videos published on October 24, 2025 in Interview with the Innovators
Importance of Hospital Partnerships for Bispecific Agent Implementation
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 21, 2025 in Interview with the Innovators
EHR Implementation of Bispecific Agents for Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 13, 2025 in Interview with the Innovators
Total Cost of Care for Bispecific Agents in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on March 10, 2025 in Interview with the Innovators
Clinical Pathways in Multiple Myeloma
Laura Bobolts, PharmD, BCOP, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, Yonatan Resnick, PharmD
Videos published on February 27, 2025 in Interview with the Innovators